These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37466080)

  • 1. Atezolizumab as the First Systemic Therapy Approved for Alveolar Soft Part Sarcoma.
    Bergsma EJ; Elgawly M; Mancuso D; Orr R; Vuskovich T; Seligson ND
    Ann Pharmacother; 2024 Apr; 58(4):407-415. PubMed ID: 37466080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Combinatorial Implications and Theranostics of Immunotherapy in the Impediment of Alveolar Soft Part Sarcoma.
    Yang Y; Beeraka NM; Liu J; Zuo X; Wang X; Li T; Fan R
    Curr Pharm Des; 2022; 28(41):3404-3412. PubMed ID: 36154597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atezolizumab for Advanced Alveolar Soft Part Sarcoma.
    Chen AP; Sharon E; O'Sullivan-Coyne G; Moore N; Foster JC; Hu JS; Van Tine BA; Conley AP; Read WL; Riedel RF; Burgess MA; Glod J; Davis EJ; Merriam P; Naqash AR; Fino KK; Miller BL; Wilsker DF; Begum A; Ferry-Galow KV; Deshpande HA; Schwartz GK; Ladle BH; Okuno SH; Beck JC; Chen JL; Takebe N; Fogli LK; Rosenberger CL; Parchment RE; Doroshow JH
    N Engl J Med; 2023 Sep; 389(10):911-921. PubMed ID: 37672694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02).
    Xie L; Liang X; Xu J; Sun X; Liu K; Sun K; Li Y; Tang X; Li X; Zhan X; Niu X; Guo W
    BMC Cancer; 2023 Sep; 23(1):868. PubMed ID: 37715133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
    Suzman DL; Agrawal S; Ning YM; Maher VE; Fernandes LL; Karuri S; Tang S; Sridhara R; Schroeder J; Goldberg KB; Ibrahim A; McKee AE; Pazdur R; Beaver JA
    Oncologist; 2019 Apr; 24(4):563-569. PubMed ID: 30541754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
    Cho BC; Abreu DR; Hussein M; Cobo M; Patel AJ; Secen N; Lee KH; Massuti B; Hiret S; Yang JCH; Barlesi F; Lee DH; Ares LP; Hsieh RW; Patil NS; Twomey P; Yang X; Meng R; Johnson ML
    Lancet Oncol; 2022 Jun; 23(6):781-792. PubMed ID: 35576957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study.
    Shi Y; Cai Q; Jiang Y; Huang G; Bi M; Wang B; Zhou Y; Wang G; Ying H; Tao Z; Shi C; Guo Q; Gao C
    Clin Cancer Res; 2020 Dec; 26(24):6445-6452. PubMed ID: 33046518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
    Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
    Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
    Nishijima TF; Shachar SS; Nyrop KA; Muss HB
    Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer.
    Mavratzas A; Seitz J; Smetanay K; Schneeweiss A; Jäger D; Fremd C
    Future Oncol; 2020 Jan; 16(3):4439-4453. PubMed ID: 31829043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.
    Kang C; Syed YY
    Drugs; 2020 Apr; 80(6):601-607. PubMed ID: 32248356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
    Herbst RS; Giaccone G; de Marinis F; Reinmuth N; Vergnenegre A; Barrios CH; Morise M; Felip E; Andric Z; Geater S; Özgüroğlu M; Zou W; Sandler A; Enquist I; Komatsubara K; Deng Y; Kuriki H; Wen X; McCleland M; Mocci S; Jassem J; Spigel DR
    N Engl J Med; 2020 Oct; 383(14):1328-1339. PubMed ID: 32997907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De-glycosylated membrane PD-L1 in tumor tissues as a biomarker for responsiveness to atezolizumab (Tecentriq) in advanced breast cancer patients.
    Ou-Yang F; Li CL; Chen CC; Shen YC; Moi SH; Luo CW; Xia WY; Wang YN; Lee HH; Wang LH; Wang SC; Pan MR; Hou MF; Hung MC
    Am J Cancer Res; 2022; 12(1):123-137. PubMed ID: 35141008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Emerging Role of PD-1/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma.
    Gwynn ME; DeRemer DL
    Ann Pharmacother; 2018 Jan; 52(1):60-68. PubMed ID: 28831813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
    Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature review.
    Su H; Yu C; Ma X; Song Q
    Invest New Drugs; 2021 Oct; 39(5):1411-1418. PubMed ID: 33765213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.
    Wilky BA; Trucco MM; Subhawong TK; Florou V; Park W; Kwon D; Wieder ED; Kolonias D; Rosenberg AE; Kerr DA; Sfakianaki E; Foley M; Merchan JR; Komanduri KV; Trent JC
    Lancet Oncol; 2019 Jun; 20(6):837-848. PubMed ID: 31078463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab.
    Hamid O; Molinero L; Bolen CR; Sosman JA; Muñoz-Couselo E; Kluger HM; McDermott DF; Powderly JD; Sarkar I; Ballinger M; Fassò M; O'Hear C; Chen DS; Hegde PS; Hodi FS
    Clin Cancer Res; 2019 Oct; 25(20):6061-6072. PubMed ID: 31358540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial.
    Judson I; Morden JP; Kilburn L; Leahy M; Benson C; Bhadri V; Campbell-Hewson Q; Cubedo R; Dangoor A; Fox L; Hennig I; Jarman K; Joubert W; Kernaghan S; López Pousa A; McNeil C; Seddon B; Snowdon C; Tattersall M; Toms C; Martinez Trufero J; Bliss JM
    Lancet Oncol; 2019 Jul; 20(7):1023-1034. PubMed ID: 31160249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors.
    Araujo-Fernandez I; Delgado J; Moscetti L; Sarac SB; Zander H; Mueller-Egert S; Dunder K; Pean E; Bergmann L; Enzmann H; Pignatti F
    ESMO Open; 2021 Feb; 6(1):100008. PubMed ID: 33399074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.